Literature DB >> 21775277

Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer.

Viren Asher1, Joanne Lee, Anni Innamaa, Anish Bali.   

Abstract

INTRODUCTION: Ovarian cancer is associated with high mortality due to presentation at advanced stage and high recurrence following treatment with chemotherapy. Most of the prognostic variables in ovarian cancer, including stage and residual disease, are amenable for assessment only after surgery. Currently there are no established preoperative markers including, CA-125, that can predict overall survival in patients with ovarian cancer. The aim of our study was to evaluate the prognostic significance of the preoperative haematological markers platelet lymphocyte ratio (PLR) and neutrophil lymphocyte ratio (NLR) in patients with ovarian cancer.
METHOD: Preoperative PLR and NLR were evaluated in 235 patients undergoing surgery for ovarian cancer. The prognostic significance of both markers was then determined by both uni- and multivariate analytical methods.
RESULTS: High preoperative PLR (p < 0.001) and NLR (p = 0.001) were significantly associated with poor survival using univariate Cox survival analysis. The median overall survival in patients with a PLR of < 300 was 37.4 months (95% CI 26.1-48.7) and 14.5 months (95% CI 11.7-17.2) in those with a PLR of > 300. PLR (p = 0.03) but not NLR (p = 0.575) retained its significance as a prognostic marker on multivariate Cox's regression analysis, along with stage (p < 0.001) and residual disease (p = 0.015).
CONCLUSION: We have shown for the first time that PLR is a novel independent prognostic marker in patients with ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21775277     DOI: 10.1007/s12094-011-0687-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  28 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer.

Authors:  S Bishara; M Griffin; A Cargill; A Bali; M E Gore; S B Kaye; J H Shepherd; P O Van Trappen
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2007-07-17       Impact factor: 2.435

Review 3.  Challenges for chemotherapy in ovarian cancer.

Authors:  R F Ozols
Journal:  Ann Oncol       Date:  2006-05       Impact factor: 32.976

4.  Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours.

Authors:  M den Ouden; J M Ubachs; J E Stoot; J W van Wersch
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1997-03       Impact factor: 2.435

5.  Tumor cell procoagulant and urokinase expression in carcinoma of the ovary.

Authors:  L R Zacharski; V A Memoli; D L Ornstein; S M Rousseau; W Kisiel; B J Kudryk
Journal:  J Natl Cancer Inst       Date:  1993-08-04       Impact factor: 13.506

6.  The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors.

Authors:  Tayfun Gungor; Mine Kanat-Pektas; Ayhan Sucak; Leyla Mollamahmutoglu
Journal:  Arch Gynecol Obstet       Date:  2008-05-10       Impact factor: 2.344

7.  Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.

Authors:  Hanbyoul Cho; Hye Won Hur; Sang Wun Kim; Sung Hoon Kim; Jae Hoon Kim; Young Tae Kim; Kook Lee
Journal:  Cancer Immunol Immunother       Date:  2008-04-15       Impact factor: 6.968

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer.

Authors:  Nuray Bozkurt; Kunter Yuce; Mustafa Basaran; Faruk Kose; Ali Ayhan
Journal:  Obstet Gynecol       Date:  2004-01       Impact factor: 7.661

10.  Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma.

Authors:  Li-li Chen; Feng Ye; Wei-Guo Lü; Yan Yu; Huai-zheng Chen; Xing Xie
Journal:  J Obstet Gynaecol Res       Date:  2009-04       Impact factor: 1.730

View more
  96 in total

1.  Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer.

Authors:  Mehmet Kos; Cemil Hocazade; F Tugba Kos; Dogan Uncu; Esra Karakas; Mutlu Dogan; Hikmet Gulsen Uncu; Nuriye Yildirim; Nurullah Zengin
Journal:  Wien Klin Wochenschr       Date:  2015-02-27       Impact factor: 1.704

Review 2.  The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer.

Authors:  Anastasia Prodromidou; Panagiotis Andreakos; Charalampos Kazakos; Dimitrios Eftimios Vlachos; Despina Perrea; Vasilios Pergialiotis
Journal:  Inflamm Res       Date:  2017-03-04       Impact factor: 4.575

3.  Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer.

Authors:  Hongbing Liu; Ying Wu; Zhaofeng Wang; Yanwen Yao; Fangfang Chen; He Zhang; Yunfen Wang; Yong Song
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

4.  Comparison of clinical utility between neutrophil count and neutrophil-lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review.

Authors:  Naoko Komura; Seiji Mabuchi; Eriko Yokoi; Katsumi Kozasa; Hiromasa Kuroda; Tomoyuki Sasano; Yuri Matsumoto; Tadashi Kimura
Journal:  Int J Clin Oncol       Date:  2017-09-26       Impact factor: 3.402

5.  INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.

Authors:  J-L Hu; X-L Hu; Q Han; A-Y Guo; C-J Wang; Y-Y Wen; S-D Cang
Journal:  Gene Ther       Date:  2017-04-24       Impact factor: 5.250

6.  Pretreatment prognostic nutritional index is a significant predictor of prognosis in patients with cervical cancer treated with concurrent chemoradiotherapy.

Authors:  Junko Haraga; Keiichiro Nakamura; Chiaki Omichi; Takeshi Nishida; Tomoko Haruma; Tomoyuki Kusumoto; Noriko Seki; Hisashi Masuyama; Norihisa Katayama; Susumu Kanazawa; Yuji Hiramatsu
Journal:  Mol Clin Oncol       Date:  2016-09-21

7.  Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.

Authors:  Wei-wei Zhang; Ke-jun Liu; Guo-lin Hu; Wei-jiang Liang
Journal:  Tumour Biol       Date:  2015-06-11

8.  Pretreatment neutrophil/lymphocyte ratio but not platelet/lymphocyte ratio has a prognostic impact in multiple myeloma.

Authors:  Yanjie Li; Hujun Li; Wenjing Li; Lijin Wang; Zhiling Yan; Yao Yao; Ruosi Yao; Kailin Xu; Zhenyu Li
Journal:  J Clin Lab Anal       Date:  2016-12-07       Impact factor: 2.352

9.  Preoperative Platelet-Lymphocyte Ratio Augments CA 19-9 as a Predictor of Malignancy in Chronic Calcific Pancreatitis.

Authors:  Ashwin Rammohan; Sathya D Cherukuri; Ravichandran Palaniappan; Senthil Kumar Perumal; Jeswanth Sathyanesan; Manoharan Govindan
Journal:  World J Surg       Date:  2015-09       Impact factor: 3.352

10.  Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion.

Authors:  M Polat; T Senol; E Ozkaya; G Ogurlu Pakay; M S Cikman; B Konukcu; M A Ozten; A Karateke
Journal:  Clin Transl Oncol       Date:  2015-08-20       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.